Showing results (421-430 of 573) with videos related to

Sort By:
Pageof 58
European Journal of Medicinal Chemistry|July 11, 2024
Design and synthesis of unique indole-benzosulfonamide oleanolic acid derivatives as potent antibacterial agents against MRSAJinxuan Li, Ying Sun, Kaize Su, et al.
Biology|July 27, 2022
Targeting the Ubiquinol-Reduction (Qi) Site of the Mitochondrial Cytochrome bc1 Complex for the Development of Next Generation Quinolone AntimalarialsKangsa Amporndanai, Nattapon Pinthong, Paul M O'Neill, et al.
Cancer Chemotherapy and Pharmacology|June 22, 2018
A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancerAmita Patnaik, Michael Gordon, Frank Tsai, et al.
Anticancer Research|April 30, 2014
Outcomes of patients with metastatic cervical cancer in a phase I clinical trials programMing-Mo Hou, Xiaochun Liu, Jennifer Wheler, et al.
ACS Medicinal Chemistry Letters|January 8, 2019
Potent Antimalarial 2-Pyrazolyl Quinolone bc 1 (Qi) Inhibitors with Improved Drug-like PropertiesW David Hong, Suet C Leung, Kangsa Amporndanai, et al.
Cancer Chemotherapy and Pharmacology|July 18, 2018
Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancerAmita Patnaik, Michael Gordon, Frank Tsai, et al.
Bioorganic Chemistry|January 8, 2021
Oleanolic acid indole derivatives as novel α-glucosidase inhibitors: Synthesis, biological evaluation, and mechanistic analysisPanpan Wu, Hao He, Hang Ma, et al.
Chemical Science|December 12, 2024
A diazirine's central carbon is sp2-hybridized, facilitating conjugation to dye moleculesLorenzo Michelini, Tanya Slaney, Seerat Virk, et al.
Oncoimmunology|December 19, 2024
Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conferencePierre-Antoine Laurent, Fabrice André, Alexandre Bobard, et al.
International Journal of Radiation Oncology, Biology, Physics|November 1, 2024
Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 TrialJay P Reddy, Alexander D Sherry, Bryan Fellman, et al.
Pageof 58